PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dapoxetine→

Dapoxetine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
119356-77-3
Molecular formula
C21H23NO
Molecular weight
305.4 g/mol
Drug class
Short-acting selective serotonin-reuptake inhibitor (SSRI)
Mechanism of action
Inhibits neuronal serotonin reuptake and increases serotonergic activity at pre- and postsynaptic receptors. Its effect on premature ejaculation is presumed to involve modulation of serotonergic control of the ejaculatory reflex.
Indications / reported uses
  • On-demand treatment of premature ejaculation in adult men who meet the applicable product-specific diagnostic and eligibility criteria; the cited EU/UK product indication covers men aged 18–64 years

Sources: NICE evidence summary — Dapoxetine for premature ejaculation · EMA referral — Priligy · European Association of Urology guideline

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Dapoxetine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dapoxetine Permitted Daily Exposure (PDE) report (the Dapoxetine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dapoxetine Occupational Exposure Limit (OEL) report (the Dapoxetine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.